BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Netw Open. 2019;2:e190035. [PMID: 30794298 DOI: 10.1001/jamanetworkopen.2019.0035] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Paroder M, Le N, Pham HP, Thibodeaux SR. Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells. Adv Cell Gene Ther 2020;3. [DOI: 10.1002/acg2.75] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 2021. [PMID: 34310745 DOI: 10.1002/ajh.26301] [Reference Citation Analysis]
3 Nukala U, Rodriguez Messan M, Yogurtcu ON, Wang X, Yang H. A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy. AAPS J 2021;23:52. [PMID: 33835308 DOI: 10.1208/s12248-021-00579-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol 2020;10:849. [PMID: 32670869 DOI: 10.3389/fonc.2020.00849] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
5 Jakobsen LH, Callréus T, Sessa M, Jerkeman M, Andersen M, El-Galaly TC. Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma. Pharmacoepidemiol Drug Saf 2021;30:514-9. [PMID: 33432654 DOI: 10.1002/pds.5195] [Reference Citation Analysis]
6 Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Clin Ther 2021:S0149-2918(21)00242-3. [PMID: 34380609 DOI: 10.1016/j.clinthera.2021.06.011] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Reiser V. Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications. J Adv Pract Oncol 2020;11:159-67. [PMID: 33532115 DOI: 10.6004/jadpro.2020.11.2.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Palomba ML, Jun MP, Lymp J, Nguyen A, McGarvey N, Gitlin M, Pelletier C, Keating SJ, Godwin J. Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. Leuk Lymphoma 2021;:1-8. [PMID: 34018458 DOI: 10.1080/10428194.2021.1910686] [Reference Citation Analysis]
9 Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Front Immunol 2020;11:888. [PMID: 32477359 DOI: 10.3389/fimmu.2020.00888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
10 Baumgardner JR, Brauer MS, Zhang J, Hao Y, Liu Z, Lakdawalla DN. CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments. Journal of Comparative Effectiveness Research 2020;9:327-40. [DOI: 10.2217/cer-2019-0065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Sussman M, Crivera C, Benner J, Adair N. Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review. Adv Ther 2021;38:4178-94. [PMID: 34251651 DOI: 10.1007/s12325-021-01841-4] [Reference Citation Analysis]
12 Whittington MD, McQueen RB, Campbell JD. Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications. J Clin Oncol 2020;38:359-66. [PMID: 31804859 DOI: 10.1200/JCO.19.01558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
13 Halford Z, Anderson MK, Bennett LL. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Ann Pharmacother 2021;55:390-405. [PMID: 32698673 DOI: 10.1177/1060028020944233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
15 Patel A, Oluwole O, Savani B, Dholaria B. Taking a BiTE out of the CAR T space race. Br J Haematol 2021. [PMID: 34131894 DOI: 10.1111/bjh.17622] [Reference Citation Analysis]
16 Campbell JD, Whittington MD. Paying for CAR-T Therapy Amidst Limited Health System Resources. J Clin Oncol 2019;37:2095-7. [PMID: 31157580 DOI: 10.1200/JCO.19.01113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
17 Schirrmacher V. Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines 2020;8:E61. [PMID: 32188078 DOI: 10.3390/biomedicines8030061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
18 Locke FL, Go WY, Neelapu SS. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. JAMA Oncol 2020;6:281-90. [PMID: 31697310 DOI: 10.1001/jamaoncol.2019.3869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
19 Hunter BD, Rogalski M, Jacobson CA. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opinion on Biological Therapy 2019;19:1157-64. [DOI: 10.1080/14712598.2019.1644316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, Sonneveld P, Sierra J, Smand C, Uyl-de Groot CA. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. Hemasphere 2021;5:e524. [PMID: 33880433 DOI: 10.1097/HS9.0000000000000524] [Reference Citation Analysis]
21 Geethakumari PR, Ramasamy DP, Dholaria B, Berdeja J, Kansagra A. Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. Curr Hematol Malig Rep 2021;16:345-56. [PMID: 34089485 DOI: 10.1007/s11899-021-00635-3] [Reference Citation Analysis]
22 van Overbeeke E, Michelsen S, Toumi M, Stevens H, Trusheim M, Huys I, Simoens S. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021;26:399-415. [PMID: 33242695 DOI: 10.1016/j.drudis.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant 2020;55:1706-15. [PMID: 32474570 DOI: 10.1038/s41409-020-0956-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 20.0] [Reference Citation Analysis]
24 Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res 2019;19:645-61. [PMID: 31623476 DOI: 10.1080/14737167.2019.1680288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, Snyder S, McGarvey N, Gitlin M, Pelletier C, Jun MP. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv 2021;5:1695-705. [PMID: 33720336 DOI: 10.1182/bloodadvances.2020003531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ 2021;24:458-68. [PMID: 33691581 DOI: 10.1080/13696998.2021.1901721] [Reference Citation Analysis]
27 El-galaly TC, Cheah CY, Kristensen D, Hutchison A, Hay K, Callréus T, Villa D. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. Acta Oncologica 2020;59:766-74. [DOI: 10.1080/0284186x.2020.1741680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]